Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Seaforth ... follow up...
4
May 23, 2008 08:39AM

Re: Seaforth ... follow up...

posted on May 23, 2008 09:14AM

Being on the BOD's of Perigrine that meets about 5 times a year is in my opinion still retired.

Being a CEO working full time for a publicly traded company dosn't sound like retirement to me.

If you had to pick one that would allow you to spend more time with your family which would it be?

Get the picture?

The thing about common sence is that it's not that common.

Steve

3
May 23, 2008 09:39AM

May 23, 2008 09:53AM
4
May 23, 2008 10:00AM
1
May 23, 2008 10:07AM
1
May 23, 2008 10:09AM
2
May 23, 2008 10:13AM

May 23, 2008 10:16AM
1
May 23, 2008 10:19AM

May 23, 2008 10:26AM
3
May 23, 2008 10:36AM
1
May 23, 2008 10:39AM
2
May 23, 2008 10:41AM
1
May 23, 2008 10:49AM
1
May 23, 2008 10:54AM

May 23, 2008 10:56AM
1
May 23, 2008 11:05AM
1
May 23, 2008 11:25AM
3
May 23, 2008 11:49AM

May 23, 2008 12:28PM
5
May 23, 2008 01:41PM

May 23, 2008 02:17PM
1
May 23, 2008 05:27PM
1
May 23, 2008 06:20PM
1
May 23, 2008 06:46PM
1
May 23, 2008 07:33PM
7
May 24, 2008 07:05AM
6
May 24, 2008 07:44AM
5
May 24, 2008 07:49AM
2
May 24, 2008 07:52AM
9
May 24, 2008 08:04AM
3
May 24, 2008 08:16AM
1
May 24, 2008 08:17AM
2
May 24, 2008 08:20AM
3
May 24, 2008 08:21AM
1
May 24, 2008 08:30AM
3
May 24, 2008 08:45AM
4
May 24, 2008 09:00AM
2
May 24, 2008 09:07AM

May 24, 2008 09:23AM
1
May 24, 2008 10:07AM
3
May 24, 2008 10:26AM
4
May 24, 2008 02:34PM
1
May 24, 2008 11:28PM
8
May 25, 2008 07:50AM

May 25, 2008 07:56AM
5
May 25, 2008 08:26AM
3
May 25, 2008 08:56AM
3
May 25, 2008 08:59AM
1
May 25, 2008 09:12AM
2
May 25, 2008 09:15AM
11
May 25, 2008 11:14AM
1
May 25, 2008 11:55AM
7
May 25, 2008 02:40PM
4
May 25, 2008 02:57PM

May 26, 2008 08:33AM
1
May 26, 2008 11:42AM
6
May 26, 2008 03:15PM
3
May 26, 2008 03:54PM
Share
New Message
Please login to post a reply